Loncastuximab for High-Risk Relapsed/Refractory FL | Juan Pablo Alderuccio, MD | ASH 2023

Results from Venetoclax Added to CLAD Combo for Older Patients With AML | Tapan Kadia, MD | ASH 2023

Costs & Financial Hardship Among BMT CTN 1102 Patients MDS | Christopher Su, MD | ASH 2023

Trial of an Education Video for CAR T-cell Therapy Recipients

Costs of Venetoclax-Obinutuzumab vs. BTKi in CLL | Scott Huntington, MD, MPH, MSc | ASH 2023

Moving to a Fully Oral Drug Combination for Older/Frail AML Patients | Tapan Kadia, MD | ASH 2023

Exploring Drug Options for MDS Patients with XPO1 Inhibitors | Justin Taylor, MD & Sana Chaudhry, BS | ASH 2023

Extending AML Remissions with Hypomethylating Agents and Venetoclax | Tapan Kadia, MD | ASH 2023

Fighting DLBCL by Attacking the Microenviroment | Leandro Cerchietti, MD | ASH 2023

Older Patients Experience Improved QOL with NHL Treatments

Effects of Stem Cell Infusion with BCMA CAR-T | Meera Mohan, MD | ASH 2023

Real World Teclistamab Results for Relapsed Refractory Myeloma Patients | Meera Mohan, MD | ASH 2023

Moving Towards Immunotherapy for Newly Diagnosed DLBCL Patients | Paolo Strati, MD | ASH 2023

Updates to Management of CAR-T and Teclistamab for Myeloma Patients | Radhika Bansal, MD | ASH 2023

iStopMM Trial in Iceland #myeloma | Jón Þórir Óskarsson, MSc | ASH 2023

Impact of Financial Toxicity and Time Toxicity in Myeloma QOL | Rahul Banerjee, MD, FACP | ASH 2023

Real-World Bortezomib Patterns in Newly Diagnosed Myeloma | Gurbakhash Kaur, MD, MA | ASH 2023

Fine Particulate Matter and Myeloma Outcomes in Urban Cohort | Michael Wysota, MD | ASH 2023

Genomic Profiling in High-Risk Smoldering Myeloma | Benjamin Diamond, MD | ASH 2023

Dexamethasone Dose Strength Impact in Newly Diagnosed Myeloma | Rahul Banerjee, MD, FACP | ASH 2023

CAR-T in Myeloma Patients with Extramedullary and Paramedullary Disease | Darren Pan, MD | ASH 2023

Real-World Patient Profile and Dosing of Teclistamab in Myeloma | Carlyn Rose Tan, MD | ASH 2023

Updates to Wearable Tech and Early Detection of CRS in Patients | Sridevi Rajeeve, MD | ASH 2023

Real-World Results from Talquetamab and Bispecific Antibodies | Carolina Schinke, MD | ASH 2023